ORF2

ROME Publishes Landmark Nature Paper Revealing First High-Resolution Structure of LINE-1 Reverse Transcriptase (RT) for Drug Discovery

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Health, Genetics, Science, Research, Therapy, Disease, Animation, Protein, Cytoplasm, Multimedia, Inflammation, Biochemistry, Autoimmune disease, Visual Science, Genome, RT, ORF2, 3D, Cancer, Autoimmunity, Pharmaceutical industry, Vaccine, Nature

ROME Therapeutics , a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, today announced a landmark publication in Nature revealing the first high-resolution structure of the LINE-1 reverse transcriptase (RT).

Key Points: 
  • ROME Therapeutics , a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, today announced a landmark publication in Nature revealing the first high-resolution structure of the LINE-1 reverse transcriptase (RT).
  • The supporting research was co-led by ROME as part of a significant collaboration with more than a dozen leading academic groups and industry organizations.
  • View the full release here: https://www.businesswire.com/news/home/20231214251491/en/
    LINE-1 reverse transcriptase (orange) can produce RNA-DNA hybrids in the cytoplasm, a new study finds.
  • These aberrant products can trigger inflammation, and might explain how LINE-1 contributes to autoimmune disease and other disease biology.